Hanmi Pharm Toekomstige groei
Future criteriumcontroles 1/6
Hanmi Pharm zal naar verwachting groeien in winst en omzet met respectievelijk 7.3% en 7.4% per jaar. De winst per aandeel zal naar verwachting groeien met 6.9% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting 15.5% zijn.
Belangrijke informatie
7.3%
Groei van de winst
6.9%
Groei van de winst per aandeel
Pharmaceuticals winstgroei | 37.9% |
Inkomstengroei | 7.4% |
Toekomstig rendement op eigen vermogen | 15.5% |
Dekking van analisten | Good |
Laatst bijgewerkt | 04 Nov 2024 |
Recente toekomstige groei-updates
Recent updates
Does Hanmi Pharm (KRX:128940) Have A Healthy Balance Sheet?
Nov 01Does Hanmi Pharm (KRX:128940) Deserve A Spot On Your Watchlist?
Oct 17Hanmi Pharm. Co., Ltd. (KRX:128940) Shares Could Be 36% Below Their Intrinsic Value Estimate
Aug 16Pinning Down Hanmi Pharm. Co., Ltd.'s (KRX:128940) P/E Is Difficult Right Now
Jul 31Do Hanmi Pharm's (KRX:128940) Earnings Warrant Your Attention?
Jul 16Hanmi Pharm (KRX:128940) Seems To Use Debt Rather Sparingly
Jun 11A Look At The Intrinsic Value Of Hanmi Pharm. Co., Ltd. (KRX:128940)
May 08Hanmi Pharm. Co., Ltd.'s (KRX:128940) Share Price Not Quite Adding Up
Apr 22Calculating The Intrinsic Value Of Hanmi Pharm. Co., Ltd. (KRX:128940)
Mar 15Hanmi Pharm (KRX:128940) Use Of Debt Could Be Considered Risky
Feb 16What Percentage Of Hanmi Pharm. Co., Ltd. (KRX:128940) Shares Do Insiders Own?
Jan 17Hanmi Pharm's (KRX:128940) Stock Price Has Reduced 48% In The Past Five Years
Dec 22Hanmi Pharm. Co., Ltd. (KRX:128940) Shares Could Be 22% Below Their Intrinsic Value Estimate
Nov 24Winst- en omzetgroeiprognoses
Datum | Inkomsten | Inkomsten | Vrije kasstroom | Geldmiddelen uit operationele activiteiten | Gem. Aantal analisten |
---|---|---|---|---|---|
12/31/2026 | 1,871,593 | 217,367 | 259,096 | 297,980 | 16 |
12/31/2025 | 1,735,367 | 188,986 | 235,787 | 278,238 | 17 |
12/31/2024 | 1,589,382 | 162,650 | 272,975 | 288,788 | 11 |
6/30/2024 | 1,568,781 | 184,377 | 198,396 | 253,078 | N/A |
3/31/2024 | 1,533,383 | 158,086 | 215,064 | 266,810 | N/A |
12/31/2023 | 1,490,887 | 146,231 | 173,029 | 216,538 | N/A |
9/30/2023 | 1,419,708 | 131,316 | 93,449 | 133,068 | N/A |
6/30/2023 | 1,397,244 | 101,982 | 98,900 | 139,958 | N/A |
3/31/2023 | 1,371,607 | 106,424 | 100,087 | 142,458 | N/A |
12/31/2022 | 1,331,547 | 82,792 | 111,618 | 162,269 | N/A |
9/30/2022 | 1,330,854 | 80,780 | 212,242 | 258,668 | N/A |
6/30/2022 | 1,291,788 | 78,807 | 222,898 | 267,987 | N/A |
3/31/2022 | 1,253,997 | 67,497 | 242,072 | 281,103 | N/A |
12/31/2021 | 1,203,186 | 67,025 | 167,776 | 201,923 | N/A |
9/30/2021 | 1,130,015 | 77,337 | 186,309 | 227,481 | N/A |
6/30/2021 | 1,093,865 | 23,092 | 145,080 | 185,482 | N/A |
3/31/2021 | 1,057,969 | 23,462 | 92,160 | 139,157 | N/A |
12/31/2020 | 1,075,854 | 11,959 | 93,785 | 151,535 | N/A |
9/30/2020 | 1,101,450 | -1,238 | 27,417 | 114,463 | N/A |
6/30/2020 | 1,100,225 | 36,049 | -15,536 | 121,852 | N/A |
3/31/2020 | 1,127,208 | 46,907 | -118,323 | 64,277 | N/A |
12/31/2019 | 1,113,650 | 52,110 | -165,540 | 12,447 | N/A |
9/30/2019 | 1,104,465 | 29,815 | -151,837 | 52,148 | N/A |
6/30/2019 | 1,074,014 | 34,892 | -178,529 | 11,181 | N/A |
3/31/2019 | 1,044,929 | 29,971 | -167,121 | 54,106 | N/A |
12/31/2018 | 1,015,962 | 24,891 | -184,829 | 25,982 | N/A |
9/30/2018 | 954,879 | 41,003 | -253,511 | -57,022 | N/A |
6/30/2018 | 947,203 | 50,120 | -286,240 | -61,733 | N/A |
3/31/2018 | 928,713 | 49,170 | N/A | -58,807 | N/A |
12/31/2017 | 916,586 | 60,434 | N/A | -62,905 | N/A |
9/30/2017 | 856,033 | 12,415 | N/A | -499 | N/A |
6/30/2017 | 848,177 | -3,433 | N/A | 8,921 | N/A |
3/31/2017 | 859,901 | 4,177 | N/A | 3,461 | N/A |
12/31/2016 | 882,725 | 23,326 | N/A | 412,965 | N/A |
9/30/2016 | 1,300,579 | 220,192 | N/A | 473,881 | N/A |
6/30/2016 | 1,349,235 | 188,682 | N/A | 439,648 | N/A |
3/31/2016 | 1,359,164 | 179,858 | N/A | 464,276 | N/A |
12/31/2015 | 1,317,535 | 154,443 | N/A | 101,712 | N/A |
9/30/2015 | 939,070 | 9,750 | N/A | -35,497 | N/A |
6/30/2015 | 850,027 | 37,587 | N/A | 1,946 | N/A |
3/31/2015 | 791,905 | 33,760 | N/A | -35,048 | N/A |
12/31/2014 | 761,280 | 35,510 | N/A | -32,820 | N/A |
9/30/2014 | 743,779 | 32,302 | N/A | -9,178 | N/A |
6/30/2014 | 750,634 | 45,249 | N/A | 16,754 | N/A |
3/31/2014 | 743,951 | 45,870 | N/A | 56,428 | N/A |
12/31/2013 | 730,134 | 43,933 | N/A | 85,992 | N/A |
Toekomstige groeivoorspellingen analisten
Verdiensten versus spaarpercentage: De verwachte winstgroei A128940 ( 7.3% per jaar) ligt boven de spaarquote ( 2.7% ).
Winst versus markt: De winst van A128940 ( 7.3% per jaar) zal naar verwachting langzamer groeien dan de markt KR ( 29.2% per jaar).
Hoge groeiwinsten: De winst van A128940 zal naar verwachting groeien, maar niet aanzienlijk.
Omzet versus markt: De omzet van A128940 ( 7.4% per jaar) zal naar verwachting langzamer groeien dan de markt KR ( 9.9% per jaar).
Hoge groei-inkomsten: De omzet van A128940 ( 7.4% per jaar) zal naar verwachting langzamer groeien dan 20% per jaar.
Groeiprognoses winst per aandeel
Toekomstig rendement op eigen vermogen
Toekomstige ROE: Het rendement op eigen vermogen A128940 zal naar verwachting over 3 jaar laag zijn ( 15.5 %).